These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23128968)

  • 1. Effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial Doppler (ECLIPse): a multicenter, randomized, double-blind, placebo-controlled trial.
    Han SW; Lee SS; Kim SH; Lee JH; Kim GS; Kim OJ; Koh IS; Lee JY; Suk SH; Lee SI; Nam HS; Kim WJ; Yong SW; Lee KY; Park JH
    Eur Neurol; 2013; 69(1):33-40. PubMed ID: 23128968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cilostazol decreases cerebral arterial pulsatility in patients with mild white matter hyperintensities: subgroup analysis from the Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse) study.
    Han SW; Song TJ; Bushnell CD; Lee SS; Kim SH; Lee JH; Kim GS; Kim OJ; Koh IS; Lee JY; Suk SH; Lee SI; Nam HS; Kim WJ; Lee KY; Park JH; Kim JY; Park JH
    Cerebrovasc Dis; 2014; 38(3):197-203. PubMed ID: 25300977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial.
    Lee YS; Bae HJ; Kang DW; Lee SH; Yu K; Park JM; Cho YJ; Hong KS; Kim DE; Kwon SU; Lee KB; Rha JH; Koo J; Han MG; Lee SJ; Lee JH; Jung SW; Lee BC; Kim JS
    Cerebrovasc Dis; 2011; 32(1):65-71. PubMed ID: 21613787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Uric Acid Is Associated with Cerebral White Matter Hyperintensities in Patients with Acute Lacunar Infarction.
    Han SW; Song TJ; Bushnell CD; Lee SS; Kim SH; Lee JH; Kim GS; Kim OJ; Koh IS; Lee JY; Suk SH; Lee SI; Nam HS; Lee KY; Park JH
    J Neuroimaging; 2016 May; 26(3):351-4. PubMed ID: 26458336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis.
    Kwon SU; Cho YJ; Koo JS; Bae HJ; Lee YS; Hong KS; Lee JH; Kim JS
    Stroke; 2005 Apr; 36(4):782-6. PubMed ID: 15746463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial.
    Lee JH; Cha JK; Lee SJ; Ha SW; Kwon SU
    Eur J Neurol; 2010 Mar; 17(3):434-42. PubMed ID: 19922458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial.
    Jeng JS; Sun Y; Lee JT; Lin RT; Chen CH; Po HL; Lin HJ; Liu CH; Sun MH; Sun MC; Chern CM; Lien LM; Chiu HC; Hu HH; Chiou HY; Chen ST; Ma H; Hsu CY;
    Int J Stroke; 2015 Jan; 10(1):123-7. PubMed ID: 25394855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
    Angiolillo DJ; Capranzano P; Goto S; Aslam M; Desai B; Charlton RK; Suzuki Y; Box LC; Shoemaker SB; Zenni MM; Guzman LA; Bass TA
    Eur Heart J; 2008 Sep; 29(18):2202-11. PubMed ID: 18567918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study.
    Shinohara Y; Gotoh F; Tohgi H; Hirai S; Terashi A; Fukuuchi Y; Otomo E; Itoh E; Matsuda T; Sawada T; Yamaguchi T; Nishimaru K; Ohashi Y
    Cerebrovasc Dis; 2008; 26(1):63-70. PubMed ID: 18511873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial.
    Douglas JS; Weintraub WS; Holmes D
    Clin Cardiol; 2003 Oct; 26(10):451-4. PubMed ID: 14579914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial.
    Hong KS; Kim BJ; Lee JY; Kwon SU;
    Int J Stroke; 2015 Oct; 10(7):1153-8. PubMed ID: 26044566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy.
    Angiolillo DJ; Capranzano P; Ferreiro JL; Ueno M; Capodanno D; Dharmashankar K; Darlington A; Sumner S; Desai B; Charlton RK; Box LC; Zenni M; Guzman LA; Bass TA
    Thromb Haemost; 2011 Aug; 106(2):253-62. PubMed ID: 21614414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.
    Guo JJ; Xu E; Lin QY; Zeng GL; Xie HF
    Neurosci Bull; 2009 Dec; 25(6):383-90. PubMed ID: 19927175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study.
    Takase B; Nagata M; Hattori H; Tanaka Y; Ishihara M
    Med Princ Pract; 2014; 23(1):59-65. PubMed ID: 24216721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.
    Huang Y; Cheng Y; Wu J; Li Y; Xu E; Hong Z; Li Z; Zhang W; Ding M; Gao X; Fan D; Zeng J; Wong K; Lu C; Xiao J; Yao C;
    Lancet Neurol; 2008 Jun; 7(6):494-9. PubMed ID: 18456558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
    Hiatt WR; Money SR; Brass EP
    J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis.
    Kwon SU; Hong KS; Kang DW; Park JM; Lee JH; Cho YJ; Yu KH; Koo JS; Wong KS; Lee SH; Lee KB; Kim DE; Jeong SW; Bae HJ; Lee BC; Han MK; Rha JH; Kim HY; Mok VC; Lee YS; Kim GM; Suwanwela NC; Yun SC; Nah HW; Kim JS
    Stroke; 2011 Oct; 42(10):2883-90. PubMed ID: 21799173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study.
    Matsumoto M
    Atheroscler Suppl; 2005 Dec; 6(4):33-40. PubMed ID: 16275125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study.
    Han Y; Li Y; Wang S; Jing Q; Wang Z; Wang D; Shu Q; Tang X
    Am Heart J; 2009 Apr; 157(4):733-9. PubMed ID: 19332203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial.
    Wong KS; Chen C; Fu J; Chang HM; Suwanwela NC; Huang YN; Han Z; Tan KS; Ratanakorn D; Chollate P; Zhao Y; Koh A; Hao Q; Markus HS;
    Lancet Neurol; 2010 May; 9(5):489-97. PubMed ID: 20335070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.